Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.
We reviewed the clinical use of daptomycin in daily practice. Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h. Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34.3%) and Enterococcus spp. in 8.7%. Clinical success was 75% and microbiological eradication 48.6%. Two patients discontinued daptomycin due to hemolytic anemia of unlikely and possible relationship with daptomycin, respectively. Daptomycin was effective and well tolerated in patients with severe Gram-positive infections.